{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.9","value":"3920"},{"groupId":"OG001","spread":"58.0","value":"5220"},{"groupId":"OG002","spread":"11.1","value":"8750"},{"groupId":"OG004","spread":"0.0","value":"5720"},{"groupId":"OG005","spread":"0.0","value":"7272"},{"groupId":"OG006","spread":"59.4","value":"4730"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"title":"AUC0-24h"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.3","value":"4260"},{"groupId":"OG001","spread":"91.8","value":"4350"},{"groupId":"OG002","spread":"24.5","value":"7670"},{"groupId":"OG003","spread":"0.0","value":"4860"},{"groupId":"OG004","spread":"48.6","value":"3730"},{"groupId":"OG005","spread":"49.1","value":"5760"},{"groupId":"OG006","spread":"32.6","value":"4940"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"AUClast"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"Characterize single and multiple-dose PK of LDK378 in pediatric patients. AUC: Area under the plasma (serum, or blood) concentration versus time curve AUClast: Area under the concentration-time curve from time zero to the last measureable concentration time AUC0-24h: Area under the plasma concentration-time curve t=0-24 h","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in the fasted group who took 300 mg of ceritinib","id":"OG000","title":"Fasted: Ceritinib 300 mg/m2"},{"description":"Participants in the fasted group who took 450 mg of ceritinib","id":"OG001","title":"Fasted: Ceritinib 450 mg/m2"},{"description":"Participants in the fasted group who took 510 mg of ceritinib","id":"OG002","title":"Fasted: Ceritinib 510 mg/m2"},{"description":"Participants in the fasted group who took 560 mg of ceritinib","id":"OG003","title":"Fasted: Ceritinib 560 mg/m2"},{"description":"Participants in the fed group who took 320 mg of ceritinib","id":"OG004","title":"Fed: Ceritinib 320 mg/m2"},{"description":"Participants in the fed group who took 400 mg of ceritinib","id":"OG005","title":"Fed: Ceritinib 400 mg/m2"},{"description":"Participants in the fed group who took 500 mg of ceritinib","id":"OG006","title":"Fed: Ceritinib 500 mg/m2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set (PAS) consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"0hr pre-dose, 2, 4, 6 & 24hrs post-dose","title":"Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 1 Day 1 - Dose Escalation Phase (Single Dose)","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}